Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema by unknown




versus aflibercept for treating Greek patients 
with visual impairment due to diabetic macular 
edema
Georgia Kourlaba1*, John Relakis2, Ronan Mahon3, Maria Kalogeropoulou4, Georgia Pantelopoulou4, 
Olga Kousidou4 and Nikos Maniadakis2
Abstract 
Background: To conduct a cost-utility analysis of ranibizumab versus aflibercept for the treatment of patients with 
visual impairment due to diabetic macular edema (DME) in the Greek setting.
Methods: A Markov model was adapted to compare the use of ranibizumab 0.5 mg (pro re nata-PRN and treat and 
extend-T&E) to aflibercept 2 mg (every 8 weeks after five initial doses) in DME. Patients transitioned at a 3-month cycle 
among nine specified health states (including death) over a lifetime horizon. Transition probabilities, utilities, as well as 
DME-related mortality were extracted from relevant clinical trials, a network meta-analysis and other published stud-
ies. The analysis was conducted from payer perspective and as such only costs reimbursed by the payer were consid-
ered (year 2014). The incremental cost per quality-adjusted life year (QALY) gained and the net monetary benefit was 
the main outcome measures.
Results: Τhe use of PRN and T&E ranibizumab regimens were shown to be cost saving comparing to aflibercept (by 
€2824 and €22, respectively), and more beneficial in terms of QALYs gained (+0.05) and time without visual impair-
ment (0.031 and 0.034 years), thereby dominating aflibercept. Moreover, ranibizumab used as PRN or T&E resulted in a 
net monetary benefit of €3984 and €1278, respectively.
Conclusions: Both PRN and T&E ranibizumab regimens were more beneficial and less costly compared to aflibercept 
for the management of DME. Hence, ranibizumab seems to be a dominant option for the treatment of visual impair-
ment due to DME in the Greek setting.
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Background
Diabetic retinopathy (DR) and diabetic macular edema 
(DME) are microvascular complications diagnosed in 
patients with diabetes mellitus [1]. Diabetic retinopathy 
represents a complication caused by damage to the blood 
vessels of the light-sensitive tissue at the back of the eye 
(retina) [2]. Diabetic macular edema occurs in a sub-
set of population with DR; it is caused by thickening of 
tissue within the macula (the central area of the retina) 
as a result of fluid leaking from the blood capillaries [3]. 
This alteration in the structure of the macula disrupts the 
function of the retina and when it affects the centre of the 
macula, it may have a sudden and debilitating impact on 
visual acuity (VA), eventually leading to blindness [1].
Risk factors for the development of DME include 
longer duration of diabetes, progression in retinopathy, 
poor glucose control and hyperlipidemia [4, 5]. Epide-
miological studies estimate that the overall prevalence of 
DME in the United States (US) and Europe ranges from 
0.85 to 12.3  %, depending on type of diabetes (one or 
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two), insulin versus non-insulin dependence, and dura-
tion of disease (years since diagnosis) [6].
Due to visual impairment (VI), and an imminent blind-
ness, the ability of patients to manage their disease as 
well as the underlying diabetes is reduced [6]. Indeed, the 
disease is associated with a significant impact on health-
related quality of life (HRQoL) in patients with diabetes 
[7–9]. In a US study measuring the utilities related with 
treatments and complications of diabetes, DR was associ-
ated with a utility of 0.53, whereas blindness had a mean 
utility of 0.38, ranked as the third lowest among all health 
states studied, following major stroke (0.31) and end-
stage renal disease (0.35) [10]. However, this negative 
impact on patients’ perceived functional status and qual-
ity of life is considered to attenuate with treatment [9].
Consequently, there is a profound economic burden for 
patients and the society overall. DME is the leading cause 
of blindness among working-age populations in most 
developed countries [11–13]. Moreover, DME patients are 
associated with higher rates of resource use (e.g. doctor 
visits, hospitalizations, diagnostic modalities, treatments 
and maintenance medications) compared to diabetic 
patients without retinal diseases or with other types of 
diabetic retinopathy [14–16]. According to Happich et al., 
DME patients in Germany use almost twice the medical 
resources of patients with mild or moderate non-prolifer-
ative DR [17]. Similarly, Shea et al. reported that Medicare 
costs for DME patients in the US were more than 30  % 
higher than for diabetic patients without retinal disease at 
1 and 3 years after diagnosis, while inpatient costs consti-
tuted almost half of the total costs [14].
For decades, standard treatments for DME have been 
based on intensive control of systemic metabolic factors 
as well as photocoagulation providing improved out-
comes in large randomized clinical trials (RCTs) [18]. 
Notwithstanding, visual loss continues to increase in 
many patients despite the aforementioned therapies, 
giving impetus to research for new DME pharmaco-
therapies. Currently, both intravitreal corticosteroids 
and intravitreal anti-vascular endothelial growth factor 
(VEGF) agents are widely used in clinical settings.
VEGF-A is a major mediator of increased vascular 
endothelial permeability and associated retinal damage 
in DME [19–21]. Ranibizumab (Lucentis®) and afliber-
cept (Eylea®) are anti-VEGFs approved for the treatment 
of VI due to DME. Both ranibizumab and aflibercept 
are administered by intravitreal injection [22, 23]. These 
novel therapies may be effective treatment options for 
DME, but they may also impose considerable costs to 
the health care system and payers. Furthermore, the 
prolonged recession in Greece, characterized by strong 
health care budgetary constraints, necessitates the need 
to use treatments which are clinically effective but at the 
same time economically efficient, to maximize the value, 
or in other words the benefit, for the money spent in 
health care.
For this reason, an economic evaluation analysis was 
conducted to assess the cost-utility of ranibizumab ver-
sus aflibercept for the treatment of patients with VI, due 
to DME, in the Greek setting. At this point, it should be 
noted that although Bevacizumab is another widely used 
anti-VEGF drug for DME, it was not considered in our 
analysis as it has been using without being approved (off-
label use).
Methods
A cost-utility analysis (CUA) was performed to compare 
ranibizumab 0.5 mg pro re nata (PRN), and ranibizumab 
0.5 mg treat and extend (T&E), to 2 mg aflibercept every 
8 weeks after five initial monthly doses (2q8). In this con-
text, a Markov model, developed based on the require-
ments of the UK National Institute for Health and Care 
Excellence (NICE), was adapted to the Greek health care 
setting to assess the health effects (i.e. DME-related out-
comes) and associated costs for each treatment strategy 
[24]. The incremental differences between treatment 
arms for each measure were determined over a lifetime 
horizon and the comparison was captured by the incre-
mental cost per quality-adjusted life year (QALY) gained.
The analysis was performed from a payer’s perspective, 
which in this case is the Greek Health Care Insurance 
Fund (EOPYY) covering the vast majority of the Greek 
population. In this context, only direct costs reimbursed 
by the payer were included in the model. Costs and out-
comes that occurred beyond 1 year were discounted at a 
3.5 % annual rate, as recommended by NICE [25], which 
is also the standard practice in Greece as well as other 
jurisdictions.
As this study is an economic evaluation analysis and 
does not involve human subjects no ethics approval 
issues arise. Input data including human material or 
human data were derived from other published stud-
ies performed with the approval of an appropriate ethics 
committee.
Target population
The hypothetical cohort in the model reflected the gen-
eral population of patients with VI due to DME. Patients 
were assumed to attain similar baseline characteristics 
to the population included in the RESTORE trial which 
assessed the clinical efficacy and safety of ranibizumab 
0.5  mg intravitreal injection (either as monotherapy 
or combined with laser therapy): focal or diffuse DME 
due to type 1 or type 2 diabetes mellitus; mean age 
of 63  years; and at least one eye with a Best Corrected 
Visual Acuity (BCVA) score between 78 and 39 letters, 
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using the Early Treatment of Diabetic Retinopathy Study 
(ETRDS)-like VA charts at a four meters-testing distance. 
In addition, based on the RESTORE trial, a proportion of 
patients were treated in both eyes, as they had bilateral 
disease (22 %) [26].
Model structure
The model structure, in its simplified form, is displayed 
in Fig.  1. In the model, patients transitioned during 
a 3-month cycle between eight BCVA-related health 
states—and death—over a lifetime horizon (base case). 
The health states were defined by BCVA groups of two 
lines on the ETDRS eye chart, given that a change in vis-
ual acuity of ≥10 letters (≥2 lines) is considered clinically 
significant [27–31]. A half-cycle correction was applied 
to each 3-month cycle.
The model was initiated by distributing patients in the 
BCVA health states as observed in the RESTORE patient 
population at baseline [26]. Patients were treated with the 
anti-VEGF treatments in the first three years, and were 
followed throughout their lifetime to gather all of the 
costs and outcomes associated with DME. Hence, the 
model incorporated the following variables: transition 
probabilities (through BCVA health states and death); 
BCVA-related utilities; resource utilization estimates; 
and unit costs for all resources and treatments. Of note, 
adverse events were not included in the core—and there-
fore the adapted—model as the incidence rates of ocular 
adverse events, considered both clinically and economi-
cally important, were found to be low in the RESTORE 
trial [32].
Transition probabilities
For years 1–3, the actual transitions observed in the 
RESTORE study, specific for the level of VA, were applied 
to the ranibizumab PRN arm. In particular, data from 
the RESTORE study were used to reflect transitions in 
year 1 [26] and data from the RESTORE extension study 
were used for years 2–3 [33]. The relative efficacy (odds 
ratios) of ranibizumab PRN vs aflibercept—sourced 
from a network meta-analysis conducted by Régnier 
et al. [34]—was used to inform the transitions of patients 
treated with aflibercept in year 1. For the following years 
(2 and 3) the same transition probabilities as ranibizumab 
PRN were assumed. The relative efficacy of ranibizumab 
T&E vs aflibercept (used in year 1) was calculated based 
on the relative efficacy of ranibizumab PRN vs afliber-
cept [34] and the relative efficacy of ranibizumab T&E 
vs ranibizumab PRN [35]. As in the case of aflibercept, 
for years 2–3, the transition probabilities of ranibizumab 
PRN were used to predict the progression of patients in 
the ranibizumab T&E arm. Finally, from year 4 onwards 
(long-term progression), patients were assumed to not 
receive any anti-VEGF treatment, and transition prob-
abilities were calculated using data from the Wisconsin 
Epidemiologic Study of Diabetic Retinopathy (WESDR) 
[36, 37] to capture the natural decline in BCVA with-
out treatment, as no clinical trial evidence is available 
regarding effectiveness of either drug after a treatment 
of 2 years. The assumption of natural decline was applied 
equally to both drugs and as such the only effect of this 
assumption is to possibly underestimate the costs and 
effects of both drugs. A summary of inputs, regarding 
Fig. 1 Model structure
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the transition probabilities of comparators, is provided in 
Table 1, while the transition probability matrices are pro-
vided in the Additional file 1.
Due to the lack of Greek-specific data regarding mor-
tality, in the adapted model, DME-related mortality rates 
were assumed to be the same as in the UK model. In the 
core model mortality rates resulted from multiplying the 
relative risk associated with developing diabetes mellitus 
and the relative risk associated with DME by the baseline 
all-cause mortality. Hence, the RR for diabetes (1.27) was 
sourced from Hirai et al. [38] and the RR for DME (1.93) 
was sourced from Mulnier et  al. [39] resulting in a RR 
for DME related mortality of 2.45. The baseline all-cause 
mortality for Greece was sourced from the WHO [40].
Utilities
The utility values used in the analysis conducted in the 
UK based on the NICE assessment of ranibizumab for 
the treatment of DME [24] were applied to each health 
state of the model. Since in the RESTORE trial 40.2 % of 
patients were treated for the better-seeing eye (BSE) and 
59.6 % of patients were treated for their worse-seeing eye 
(WSE), utilities were specified for BSE or WSE. Moreover, 
in cases of patients with bilateral disease, the QALY gains 
from the BSE utilities were assumed. Notably, no utilities 
specific to DME are found in the literature. Hence, for BSE, 
age-adjusted utilities, originally used for wet-AMD, were 
sourced from the study of Czoski-Murray et al. [41].
Regarding WSE, utilities were sourced from a Canadian 
study conducted to assess the health state utilities asso-
ciated with BCVA in patients with retinal vein occlusion 
(RVO) [42]. It was assumed that the RVO utilities would 
be relevant for the DME patient population, as these were 
anchored by VA. The relationship between the health util-
ity scores of the study and the BCVA scores in the affected 
eye was explored using a multiple linear regression model. 
Subsequently, the regression model was used to estimate 
utilities for the 8 health states of the Markov model. The 
utility values in details are presented elsewhere [24].
Resource utilization and cost inputs
Drug acquisition costs were calculated based on hospi-
tal prices, using the latest Price Bulletin available at the 
time of the analysis, issued by the Ministry of Health 
[43], and by deducting the applicable rebates to reach 
the final drug prices reimbursed by EOPYY. Regarding 
laser surgery, patients in the Greek health care system 
can choose either the outpatient or the hospital setting 
for application. For the purposes of the adapted model it 
was assumed that 62.5 % of patients will choose the hos-
pital setting requiring a reimbursement of €177 as per 
the DRG tariffs [44]. Reimbursement for the remaining 
patients (37.5  %) undergoing surgery in the outpatient 
setting was calculated at €20.15, which corresponds to 
85 % of the €23.17 cost per visit (25 % constitutes patient 
out-of-pocket payment) [45]. Based on the aforemen-
tioned, an average cost of €118 per laser surgery was con-
sidered in the model.
The cost of blindness was assumed to be equal to the 
monthly allowance of €362 that EOPYY provides to 
the blind in the form of social payment (€4.344 annu-
ally) [46]. Although the relevant payment is covered by 
the national healthcare system in Greece, it could also 
be considered as a “transfer payment”, and therefore 
excluded from an economic analysis. The administra-
tion cost of ranibizumab (and aflibercept) was set at €66 
in the adapted model. This was estimated based on the 
specialist opinion of an expert panel, according to which 
15 % of patients pay €5 as an out-patient visit to hospitals 
which is not reimbursed by EOPYY, 35 % of patients visit 
the hospital in the regimen of the one-day clinic which 
is reimbursed as per the relevant DRG at €80, 35  % of 
patients visit the hospital in the regimen of the one-day 
surgery which is reimbursed as per the relevant DRG at 
€177 and 30  % of patients visit private physicians and 
the physician visit is reimbursed by EOPYY at €10 [44]. 
Table 2 presents the cost inputs for the model specific to 
the Greek setting.
Data analysis
The cost-utility of ranibizumab PRN and ranibizumab 
T&E compared to aflibercept was evaluated by calculat-
ing the incremental cost per QALYs gained and using a 
willingness-to-pay (WTP) threshold of €25,000. Health 
Technology Assessment is not mandatory locally and 
as such there is no pre-determined WTP threshold 
Table 1 Transition probabilities used in the model
NMA network meta-analysis; RAN PRN ranibizumab pro re nata; RAN T&E ranibizumab treat and extend; AFL aflibercept
Time period RAN PRN RAN T&E AFL
Year 1 RESTORE [26] NMA [34] + RETAIN [35] NMA [34]
Year 2 RESTORE extension [33] Assumption (same as RAN PRN) Assumption (same as RAN PRN)
Year 3 RESTORE extension [33] Assumption (same as RAN PRN) Assumption (same as RAN PRN)
Year 4+ Natural history [36, 37] Natural history [36, 37] Natural history [36, 37]
Page 5 of 9Kourlaba et al. Cost Eff Resour Alloc  (2016) 14:7 
generally applied by the Greek Authorities to make deci-
sions on the reimbursement of healthcare interventions. 
In this analysis, the WTP threshold was assumed to equal 
the equivalent willingness to pay threshold value set by 
NICE in euros (approx. €25  k at the time). In addition, 
the net monetary benefit (NMB) of ranibizumab was 
estimated; the NMB is equal to the incremental QALY 
gained multiplied by the WTP minus the incremental 
costs. A NMB, greater than zero, indicates that a treat-
ment is cost-effective in health care setting.
One-way sensitivity analysis (OWSA) was performed 
to test the robustness of the results. The independent var-
iables were varied within plausible pre-specified ranges 
in order to ascertain the key drivers of cost-effectiveness 
and check for the impact of uncertainty on the NMB. The 
following parameters have been altered: discount rate; 
time horizon; BSE Utilities; risk ratio of DME mortal-
ity; WSE utilities; starting age; Odds ratio Ranibizumab 
vs Aflibercept, rebates and costing data. The values used 
in the sensitivity analysis are presented in Table  3. The 
results are presented in the form of Tornado diagrams.
The majority of input data used in the current model 
are subjected to variation. Therefore, in order to deal with 
uncertainty, a probabilistic sensitivity analysis (PSA) was 
performed using a second-order Monte Carlo simulation. 
In this analysis, a distribution was assigned around each 
parameter (i.e. costs, transition probabilities etc.) and the 
aforementioned economic and health outcomes associ-
ated with simultaneously selecting random values from 
those distributions were generated. Distributions were 
selected based on the nature of variables [47]. A cost-
effectiveness acceptability curve (CEAC) was plotted, 
showing the proportion of simulations that are considered 
cost-effective at different levels of WTP per QALY gained.
Results
Ranibizumab PRN vs aflibercept
According to the base case results, ranibizumab PRN 
accumulated mean total life time costs of €12,180, 
whereas aflibercept accumulated costs of €15,004. In this 
context, savings due to the selection of ranibizumab PRN 
for the treatment of patients could reach €2824 over a life-
time period. Patients treated with ranibizumab PRN and 
aflibercept are expected to live 4.35 and 4.32 years with-
out visual impairment (BCVA  >35 letters), respectively. 
In addition, ranibizumab PRN generated an increment of 
0.05 QALYs when compared to aflibercept (8.59 vs 8.54). 
Since ranibizumab PRN was able to generate savings com-
bined with better health outcomes for the target popula-
tion it is considered to dominate aflibercept in the Greek 
setting. The cost-effectiveness of ranibizumab PRN was 
further indicated by the NMB of €3984 (Table 4).
Ranibizumab T&E vs aflibercept
Regarding the comparison of ranibizumab T&E versus 
aflicercept, cost savings due to the selection of ranibi-
zumab were equal to €22 (€14,982 vs €15,004) with a 
QALY gain of 0.05 (8.59 vs 8.54). Moreover, an increment 
of 0.034 years without visual impairment (BCVA >35 let-
ters) was attributed to ranibizumab T&E in relation to 
aflicercept (4.355 vs 4.321). Consequently, ranibizumab 
T&E is also considered a dominant option over aflicer-
cept in the Greek setting producing a NMB of €1278. The 
base case results for both comparisons of the analysis are 
reported in Table 4 below.
One‑way sensitivity analysis
OWSA was used to explore uncertainty around input 
values. The price of aflibercept and ranibizumab as well 
as the odd ratio of ranibizumab vs aflibercept at months 
0–3 were found to have the greater impact on the main 
results of our analysis (Figs. 2, 3). With respect to ranibi-
zumab price, we calculated that ranibizumab ceases to 
be cost-effective when its reimbursed price reaches at 
€925.30 and €723.89 in case of PRN and T&E regimens, 
respectively.
Probabilistic sensitivity analysis
The PSA confirms the deterministic results. The CEAC 
showed that at a WTP threshold of €25,000 ranibizumab 
Table 2 Cost inputs used in the Greek model
a  The prices for pharmaceutical products reported in the table are the ex-factory prices that are officially published in the Price Bulletin issued by the Greek 
authorities. The acquisition prices incorporated in the model for the purposes of this local adaptation were the hospital prices reduced by the rebates that correspond 
to the third party payer, EOPYY
Model input Costs Data source
Ranibizumab acquisition costa €781.52 Official price bulletin—Greek ministry of health; August 2014
Aflibercept acquisition cost €718.83 Official price bulletin—Greek ministry of health; August 2014
Laser therapy cost (per visit) €118 Weighted sum of the different charges as per the Greek legislature, depending on the setting of laser therapy 
(inpatient, outpatient)
Administration costs €66 Weighted sum of the different charges as per the Greek legislature, depending on the setting of administra-
tion (out-patient, hospital 1 day clinic visit, hospital 1 day surgery visit, private physician visit)
Cost of blindness (annual) €4344 Min. Dec. Π3α/Φ. 18/Γ.Π.oik.63,731; FEK 931 Β’/21-5-2008
Page 6 of 9Kourlaba et al. Cost Eff Resour Alloc  (2016) 14:7 
PRN and T&E was almost 71 and 56 % more likely to be 
cost-effective over aflibercept (Fig. 4).
Discussion
DME is a complication of DR in patients with diabetes 
mellitus. Moreover, if left untreated, DME causes vision 
loss and can eventually lead to blindness [1]. Ranibi-
zumab and aflibercept are novel anti-VEGFs approved for 
the treatment of this debilitating condition [22, 23]. The 
analysis presented here aimed to demonstrate the most 
cost-effective treatment option, in terms of health out-
comes and associated costs, for the Greek Health Care 
Insurance Fund that covers the vast majority of the Greek 
population.
Clinical studies have demonstrated the efficacy of 
ranibizumab in patients with VI due to DME over 
36 months [26, 33]. A network meta-analysis by Régnier 
et al. [34] on the efficacy of anti-VEGF and laser photo-
coagulation treatments provided the relative efficacy 
of ranibizumab PRN vs aflibercept whereas combining 
data of this analysis with data from the RETAIN trial 
[35] allowed for the calculation of the relative efficacy of 
ranibizumab T&E vs aflibercept.
By adapting a UK Markov model developed for under-
taking an economic evaluation that follows patients over 
a lifetime horizon, ranibizumab PRN and ranibizumab 
T&E were found to increase the years without visual 
impairment (BCVA >35 letters) by 0.031 and 0.034 years, 
respectively, when compared to aflibercept. Adjusting for 
preference values relative to optimal health and death for 
the time spent in each VA level, both ranibizumab PRN 
and ranibizumab T&E showed an increment of 0.05 
QALYs. Moreover the ranibizumab arms managed to 
generate cost savings for the insurance fund in Greece. In 
particular, savings for ranibizumab PRN were estimated 
at €2824 whereas savings for ranibizumab T&E were esti-
mated at €22. The NMB over aflibercept was estimated at 
€3984 for ranibizumab PRN and at €1278 for ranibizumab 
Table 3 Model inputs updated to the Greek healthcare setting used in sensitivity analysis
a  Lucentis® acquisition cost of €781.52 incorporated into the model using EOPYY rebate discount of 8%
b  Eylea® acquisition cost of €718.52 incorporated into the model using EOPYY rebate discount of 6.5%
BSE better-seeing eye; WSE worse-seeing eye; DME diabetic macular edema; BCVA best corrected visual acuity
Model input Values Low values High values Variation
Time horizon 36 10 20
Discount rate costs/outcomes 3.50 % 0 % 7.0 %
Baseline age 63 53 73 ±10 years
Utility multiplier—BSE 1 0.80 1.20 ±20 %
Utility multiplier—WSE 1 0.80 1.20 ±20 %
Relative risk mortality w DME 2.45 1.00 4.90 ±100 %
Odds ratio ranibizumab PRN vs aflibercept month 0–3 1.5949 0.61 5.37 Standard error
Odds ratio ranibizumab T&E vs aflibercept month 0–3 1.65 0.43 6.08 Standard error
Price of ranibizumab €656.16a €492.12 €820.20 ±25 % (of acquisition cost)
Price of aflibercept €613.36b €460.02 €766.70 ±25 % (of acquisition cost)
Administration cost €66.40 €49.80 €83.00 ±25 %
Monitoring visit cost €10.00 €7.50 €12.50 ±25 %
BCVA ≤35 year 1 €5248.49 €3936.37 €6560.61 ±25 %
BCVA ≤35 year 2+ €4866.49 €3649.87 €6083.11 ±25 %
Table 4 Base case results—ranibizumab PRN, and ranibizumab T&E vs aflibercept
RAN PRN ranibizumab pro re nata; RAN T&E ranibizumab treat and extend; AFL aflibercept; BCVA best corrected visual acuity; QALY quality-adjusted life year; NMB net 
monetary benefit
RAN PRN RAN T&E AFL RAN PRN vs AFL RAN T&E vs AFL
Costs €12,180 €14,982 €15,004 −€2824 −€22
Years without visual impairment (BCVA >35 letters) 4.352 4.355 4.321 +0.031 +0.034
Total QALYs 8.59 8.59 8.54 +0.05 +0.05
Cost per year without visual impairment (BCVA >35 letters) – – – −€89,807 −€653
Cost per QALY – – – Dominant Dominant
NMB €3984 €1278
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T&E. Hence, both options of ranibizumab are considered 
to dominate aflibercept in the Greek setting.
In general, the NMB of ranibizumab T&E was found 
to be more sensitive when altering parameters in the 
one-way sensitivity analysis. Nonetheless, none of the 
scenarios investigated questioned the cost-effectiveness 
of the ranibizumab arms as in all cases they dominated 
aflibercept. Potential changes in the NMB of ranibizumab 
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Fig. 2 Tornado diagram ranibizumab PRN vs aflibercept. RR relative risk; OR odds ratio; BCVA best corrected visual acuity; NMB net monetary benefit; 
BSE better-seeing eye; WSE worse-seeing eye; DME diabetic macular edema
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Fig. 3 Tornado diagram ranibizumab T&E vs aflibercept. RR relative risk; OR odds ratio; BCVA best corrected visual acuity; NMB net monetary benefit; 
BSE better-seeing eye; WSE worse-seeing eye; DME diabetic macular edema
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PRN ranged from −12.75 % (starting age: 73) to +11.30 
(discounting rate: 0  %) around the base case scenario. 
The same parameters provided the low and high range 
for the NMB of ranibizumab T&E. When starting age for 
the target population was set to 73  years the NMB was 
reduced to €869 (−32 %) while a discounting rate of 0 % 
resulted in a NMB of €1625 (+27 %).
The results of this economic analysis undertaken in the 
Greek setting were consistent with those published in the 
UK, from a health care perspective. Ranibizumab PRN 
and ranibizumab T&E resulted in lower lifetime costs 
and greater QALYs dominating aflibercept. No differ-
ences were observed in the health outcomes of the com-
parators (i.e. QALYs) [24].
The analysis pursued is characterized by specific draw-
backs and limitations. Since the analysis was undertaken 
from the perspective of Greek Health Care Insurance 
Fund, only direct medical costs for the treatment of VI 
due to DME were considered. Notwithstanding, it is 
acknowledged that the ramifications of a DME have a 
wider impact generating significant indirect costs (e.g. 
productivity losses) that could enhance the results of our 
analysis. A specific drawback regarding the adaptation 
of this cost-effectiveness model was the fact that, due 
to lack of Greek-specific studies, DME-related mortal-
ity was assumed to be the same as in the UK core model. 
Another limitation of the study was the fact that it did not 
account for variation in treatment practice (i.e. the num-
ber of injections in year 1–3 was tested). Moreover, the 
clinical inputs of the current study were extracted from 
a network meta-analysis and not a head to head study. 
Finally, within the context of customization, it should be 
noted that the results refer strictly to Greece and on the 
basis of the present time resource and drug prices. If any 
of the underlying parameters change, so may the results 
and the conclusions of the analysis.
Conclusions
This cost-utility analysis confirmed that, for DME 
patients with VI, ranibizumab 0.5  mg PRN and T&E 
regimens were associated with increased time without 
visual impairment, increased quality-adjusted survival 
and fewer costs versus Aflibercept under the EOPYY 
perspective. The model results demonstrate that ranibi-
zumab 0.5  mg PRN and T&E consist dominant options 
for the treatment of VI due to DME in the Greek health-
care setting.
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